Calprotectin--a novel marker of obesity

Ole Hartvig Mortensen; Anders Rinnov Nielsen; Christian Erikstrup; Peter Plomgaard; Christian Philip Fischer; Rikke Krogh-Madsen; Birgitte Lindegaard; Anne Marie Petersen; Sarah Taudorf; Bente Klarlund Pedersen

doi:10.1371/journal.pone.0007419

Calprotectin--a novel marker of obesity

Ole Hartvig Mortensen, Anders Rinnov Nielsen, Christian Erikstrup, Peter Plomgaard, Christian Philip Fischer, Rikke Krogh-Madsen, Birgitte Lindegaard, Anne Marie Petersen, Sarah Taudorf, Bente Klarlund Pedersen

80 Citations (Scopus)

Abstract

BACKGROUND: The two inflammatory molecules, S100A8 and S100A9, form a heterodimer, calprotectin. Plasma calprotectin levels are elevated in various inflammatory disorders. We hypothesized that plasma calprotectin levels would be increased in subjects with low-grade systemic inflammation i.e. either obese subjects or subjects with type 2 diabetes. METHODOLOGY/PRINCIPAL FINDINGS: Plasma calprotectin and skeletal muscle S100A8 mRNA levels were measured in a cohort consisting of 199 subjects divided into four groups depending on presence or absence of type 2 diabetes (T2D), and presence or absence of obesity. There was a significant interaction between obesity and T2D (p = 0.012). Plasma calprotectin was increased in obese relative to non-obese controls (p<0.0001), whereas it did not differ between obese and non-obese patients with T2D (p = 0.62). S100A8 mRNA levels in skeletal muscle were not influenced by obesity or T2D. Multivariate regression analysis (adjusting for age, sex, smoking and HOMA2-IR) showed plasma calprotectin to be strongly associated with BMI, even when further adjusted for fitness, CRP, TNF-alpha or neutrophil number. CONCLUSIONS/SIGNIFICANCE: Plasma calprotectin is a marker of obesity in individuals without type 2 diabetes.

Original language	English
Journal	PLoS ONE
Volume	4
Issue number	10
Pages (from-to)	e7419
ISSN	1932-6203
DOIs	https://doi.org/10.1371/journal.pone.0007419
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0007419

Cite this

@article{6c260e3035aa11df8ed1000ea68e967b,

title = "Calprotectin--a novel marker of obesity",

abstract = "BACKGROUND: The two inflammatory molecules, S100A8 and S100A9, form a heterodimer, calprotectin. Plasma calprotectin levels are elevated in various inflammatory disorders. We hypothesized that plasma calprotectin levels would be increased in subjects with low-grade systemic inflammation i.e. either obese subjects or subjects with type 2 diabetes. METHODOLOGY/PRINCIPAL FINDINGS: Plasma calprotectin and skeletal muscle S100A8 mRNA levels were measured in a cohort consisting of 199 subjects divided into four groups depending on presence or absence of type 2 diabetes (T2D), and presence or absence of obesity. There was a significant interaction between obesity and T2D (p = 0.012). Plasma calprotectin was increased in obese relative to non-obese controls (p<0.0001), whereas it did not differ between obese and non-obese patients with T2D (p = 0.62). S100A8 mRNA levels in skeletal muscle were not influenced by obesity or T2D. Multivariate regression analysis (adjusting for age, sex, smoking and HOMA2-IR) showed plasma calprotectin to be strongly associated with BMI, even when further adjusted for fitness, CRP, TNF-alpha or neutrophil number. CONCLUSIONS/SIGNIFICANCE: Plasma calprotectin is a marker of obesity in individuals without type 2 diabetes.",

author = "Mortensen, {Ole Hartvig} and Nielsen, {Anders Rinnov} and Christian Erikstrup and Peter Plomgaard and Fischer, {Christian Philip} and Rikke Krogh-Madsen and Birgitte Lindegaard and Petersen, {Anne Marie} and Sarah Taudorf and Pedersen, {Bente Klarlund}",

note = "Keywords: Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dimerization; Female; Humans; Inflammation; Leukocyte L1 Antigen Complex; Male; Middle Aged; Multivariate Analysis; Muscle, Skeletal; Neutrophils; Obesity; Smoking",

year = "2009",

doi = "10.1371/journal.pone.0007419",

language = "English",

volume = "4",

pages = "e7419",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "10",

}

TY - JOUR

T1 - Calprotectin--a novel marker of obesity

AU - Mortensen, Ole Hartvig

AU - Nielsen, Anders Rinnov

AU - Erikstrup, Christian

AU - Plomgaard, Peter

AU - Fischer, Christian Philip

AU - Krogh-Madsen, Rikke

AU - Lindegaard, Birgitte

AU - Petersen, Anne Marie

AU - Taudorf, Sarah

AU - Pedersen, Bente Klarlund

N1 - Keywords: Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dimerization; Female; Humans; Inflammation; Leukocyte L1 Antigen Complex; Male; Middle Aged; Multivariate Analysis; Muscle, Skeletal; Neutrophils; Obesity; Smoking

PY - 2009

Y1 - 2009

N2 - BACKGROUND: The two inflammatory molecules, S100A8 and S100A9, form a heterodimer, calprotectin. Plasma calprotectin levels are elevated in various inflammatory disorders. We hypothesized that plasma calprotectin levels would be increased in subjects with low-grade systemic inflammation i.e. either obese subjects or subjects with type 2 diabetes. METHODOLOGY/PRINCIPAL FINDINGS: Plasma calprotectin and skeletal muscle S100A8 mRNA levels were measured in a cohort consisting of 199 subjects divided into four groups depending on presence or absence of type 2 diabetes (T2D), and presence or absence of obesity. There was a significant interaction between obesity and T2D (p = 0.012). Plasma calprotectin was increased in obese relative to non-obese controls (p<0.0001), whereas it did not differ between obese and non-obese patients with T2D (p = 0.62). S100A8 mRNA levels in skeletal muscle were not influenced by obesity or T2D. Multivariate regression analysis (adjusting for age, sex, smoking and HOMA2-IR) showed plasma calprotectin to be strongly associated with BMI, even when further adjusted for fitness, CRP, TNF-alpha or neutrophil number. CONCLUSIONS/SIGNIFICANCE: Plasma calprotectin is a marker of obesity in individuals without type 2 diabetes.

AB - BACKGROUND: The two inflammatory molecules, S100A8 and S100A9, form a heterodimer, calprotectin. Plasma calprotectin levels are elevated in various inflammatory disorders. We hypothesized that plasma calprotectin levels would be increased in subjects with low-grade systemic inflammation i.e. either obese subjects or subjects with type 2 diabetes. METHODOLOGY/PRINCIPAL FINDINGS: Plasma calprotectin and skeletal muscle S100A8 mRNA levels were measured in a cohort consisting of 199 subjects divided into four groups depending on presence or absence of type 2 diabetes (T2D), and presence or absence of obesity. There was a significant interaction between obesity and T2D (p = 0.012). Plasma calprotectin was increased in obese relative to non-obese controls (p<0.0001), whereas it did not differ between obese and non-obese patients with T2D (p = 0.62). S100A8 mRNA levels in skeletal muscle were not influenced by obesity or T2D. Multivariate regression analysis (adjusting for age, sex, smoking and HOMA2-IR) showed plasma calprotectin to be strongly associated with BMI, even when further adjusted for fitness, CRP, TNF-alpha or neutrophil number. CONCLUSIONS/SIGNIFICANCE: Plasma calprotectin is a marker of obesity in individuals without type 2 diabetes.

U2 - 10.1371/journal.pone.0007419

DO - 10.1371/journal.pone.0007419

M3 - Journal article

C2 - 19823685

SN - 1932-6203

VL - 4

SP - e7419

JO - PLoS ONE

JF - PLoS ONE

IS - 10

ER -

Calprotectin--a novel marker of obesity

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this